Exogenus Therapeutics is an early-stage research and development company developing healthcare solutions based on Extracellular Vesicles (EVs) and Exosomes. Founded in 2015,
Exogenus is a pioneer in the field of EVs/Exosome-based therapeutics, and a recognized innovator in Umbilical Cord Blood clinical use. Leveraging on its experience and recognition in this space, Exogenus mission is to foster a new era of EVs/Exosomes-based solutions to solve major healthcare challenges, based on the development of its own products, and providing guidance to other partners developing this type technologies for clinical use.
Exogenus Therapeutics participated in a roundtable about “Diagnostic & therapeutic uses for extracellular vesicles (EVs)”
Exogenus Therapeutics CEO, Joana Simões Correia, participated in a roundtable organized by Cell & Gene Therapy Insights and Miltenyi, as part of a discussion panel about “Diagnostic...
Exogenus Therapeutics is co-author of the new ISEV report
A meeting report from the 2021 massivEVs workshop entitled “Large-scale production of extracellular vesicles: Report on the “massivEVs” ISEV workshop” is now online. The massivEVs workshop...
Exogenus Therapeutics is one of the winners of this year’s Blue Bio Value Accelerator
We are proud to be awarded at the 5th Blue Bio Value Accelerator, which included the participation of 18 selected startups from 12 countries. This international cohort focused on...